JP2014516536A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516536A5
JP2014516536A5 JP2014511948A JP2014511948A JP2014516536A5 JP 2014516536 A5 JP2014516536 A5 JP 2014516536A5 JP 2014511948 A JP2014511948 A JP 2014511948A JP 2014511948 A JP2014511948 A JP 2014511948A JP 2014516536 A5 JP2014516536 A5 JP 2014516536A5
Authority
JP
Japan
Prior art keywords
sequence
vector
vector according
immunogenic composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516536A (ja
JP6230527B2 (ja
Filing date
Publication date
Priority claimed from GBGB1108879.6A external-priority patent/GB201108879D0/en
Application filed filed Critical
Publication of JP2014516536A publication Critical patent/JP2014516536A/ja
Publication of JP2014516536A5 publication Critical patent/JP2014516536A5/ja
Application granted granted Critical
Publication of JP6230527B2 publication Critical patent/JP6230527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511948A 2011-05-25 2012-05-25 サルアデノウイルス及び雑種アデノウイルスベクター Active JP6230527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1108879.6 2011-05-25
GBGB1108879.6A GB201108879D0 (en) 2011-05-25 2011-05-25 Vector
PCT/GB2012/000467 WO2012172277A1 (en) 2011-05-25 2012-05-25 Simian adenovirus and hybrid adenoviral vectors

Publications (3)

Publication Number Publication Date
JP2014516536A JP2014516536A (ja) 2014-07-17
JP2014516536A5 true JP2014516536A5 (OSRAM) 2015-07-09
JP6230527B2 JP6230527B2 (ja) 2017-11-15

Family

ID=44279666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511948A Active JP6230527B2 (ja) 2011-05-25 2012-05-25 サルアデノウイルス及び雑種アデノウイルスベクター

Country Status (16)

Country Link
US (4) US9714435B2 (OSRAM)
EP (2) EP3321367B1 (OSRAM)
JP (1) JP6230527B2 (OSRAM)
CN (1) CN103930551B (OSRAM)
AU (1) AU2012270144B2 (OSRAM)
BR (1) BR112013030222A2 (OSRAM)
CA (1) CA2837274C (OSRAM)
DK (1) DK2714916T3 (OSRAM)
ES (1) ES2659183T3 (OSRAM)
FR (1) FR21C1026I1 (OSRAM)
GB (1) GB201108879D0 (OSRAM)
NO (2) NO2714916T3 (OSRAM)
RU (1) RU2013152648A (OSRAM)
SG (2) SG195181A1 (OSRAM)
WO (1) WO2012172277A1 (OSRAM)
ZA (1) ZA201309016B (OSRAM)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
MX358019B (es) * 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
GB201413530D0 (en) 2014-07-30 2014-09-10 Isis Innovation Treatment and prevention of malaria
KR102535670B1 (ko) * 2015-06-12 2023-05-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN106916851A (zh) * 2017-03-01 2017-07-04 广州恩宝生物医药科技有限公司 一种复制缺陷型人14型腺病毒载体及其制备方法和应用
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
GB201708444D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Compositions and methods for inducing an immune response
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
GB201812647D0 (en) * 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
CN109797168A (zh) * 2018-09-28 2019-05-24 广州佰芮慷生物科技有限公司 一种重组腺病毒的表达载体SAd23-L
WO2020074908A2 (en) 2018-10-10 2020-04-16 Oxford University Innovation Limited Treatment and prevention of malaria
GB201818084D0 (en) 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
TW202408568A (zh) * 2019-05-22 2024-03-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
CA3141454A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CN114072516B (zh) 2019-05-30 2025-01-14 磨石生物公司 经修饰的腺病毒
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
IL293051A (en) 2019-11-18 2022-07-01 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン
GB2594683A (en) 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine
GB202003611D0 (en) 2020-03-12 2020-04-29 Univ Oxford Innovation Ltd Stabilised viral fusion proteins
WO2021181100A1 (en) 2020-03-13 2021-09-16 Oxford University Innovation Limited Compositions and methods for inducing an immune response
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
AU2021269783A1 (en) 2020-05-11 2022-12-08 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
TWI867224B (zh) * 2020-06-08 2024-12-21 中央研究院 重組抗體或片段,以及其用途
WO2022002894A1 (en) 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
US20230302119A1 (en) 2020-07-06 2023-09-28 Janssen Pharmaceuticals, Inc. Stabilized Corona Virus Spike Protein Fusion Proteins
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
GB2596820A (en) 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
JP2023541108A (ja) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド マルチエピトープワクチンカセット
EA037291B9 (ru) * 2020-08-22 2021-11-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты)
WO2022058700A1 (en) 2020-09-15 2022-03-24 Imperial College Innovations Limited Treatment of idiopathic pulmonary fibrosis
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
GB202017673D0 (en) 2020-11-09 2020-12-23 Imperial College Innovations Ltd Treatment of pulmonary arterial hypertensive
TW202237164A (zh) * 2020-12-04 2022-10-01 美商磨石生物公司 組合物及其使用方法
GB202019454D0 (en) 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for purifying virus
GB202019455D0 (en) 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for producing virus
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前rsv fb抗原
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
US20220265813A1 (en) 2021-02-23 2022-08-25 Janssen Vaccines & Prevention B.V. Trimer Stabilizing HIV Envelope Protein Mutation
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
GB202105277D0 (en) 2021-04-13 2021-05-26 Imperial College Innovations Ltd Signal peptides
WO2022234283A1 (en) 2021-05-07 2022-11-10 Astrazeneca Uk Limited Compositions and methods for inducing an immune response
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023105221A1 (en) 2021-12-07 2023-06-15 Vaccitech (Uk) Limited Vaccine boost methods and compositions
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
IL319934A (en) 2022-10-06 2025-05-01 Msd Int Business Gmbh Stabilized pre-fusion piv3 f proteins
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4608437A2 (en) 2022-10-25 2025-09-03 Barinthus Biotherapeutics North America, Inc. Combination treatment regimes for treating cancer
GB202301244D0 (en) 2023-01-27 2023-03-15 Univ Oxford Innovation Ltd Vaccine
GB202303328D0 (en) 2023-03-07 2023-04-19 Imperial College Innovations Ltd Synthetic promoters
GB202305535D0 (en) 2023-04-14 2023-05-31 Imperial College Innovations Ltd Oligonucleotide decoy
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN117089577B (zh) * 2023-08-21 2024-06-25 暨南大学 重组的猴腺病毒、病毒载体及构建方法
WO2025052130A1 (en) 2023-09-05 2025-03-13 Oxford University Innovation Limited Monoclonal antibody directed to reticulocyte-binding protein homologue 5 (pfrh5)
GB202400424D0 (en) 2024-01-11 2024-02-28 Cancer Research Tech Ltd Treatment and prevention of lung cancer
WO2025168946A1 (en) 2024-02-09 2025-08-14 Oxford University Innovation Limited Pfrh5 immunogen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3650939A (en) 1964-11-12 1972-03-21 Ppg Industries Inc Alkali chlorine cell
CA2271450A1 (en) 1999-05-12 2000-11-12 Stuart Energy Systems Inc. Hydrogen fuel replenishment process and apparatus
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
SG2013034475A (en) * 2001-11-21 2016-10-28 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US20070205342A1 (en) 2002-01-23 2007-09-06 Edward Gabriel Slip drive for leveling devices
US7481858B2 (en) 2005-02-25 2009-01-27 Societe Bic Hydrogen generating fuel cell cartridges
EP2163260B1 (en) * 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
US7617018B2 (en) 2004-10-18 2009-11-10 Innovative Design Solutions Platform attitude adjustment augmentation method and apparatus
US7178337B2 (en) 2004-12-23 2007-02-20 Tassilo Pflanz Power plant system for utilizing the heat energy of geothermal reservoirs
CN100578676C (zh) * 2005-01-12 2010-01-06 明基电通股份有限公司 可调式升降支撑装置
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
EP2333091B1 (en) * 2007-05-29 2017-06-21 Nature Technology Corporation Vectors and methods for genetic immunization
SI2220241T1 (sl) * 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
CA2754743C (en) * 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector

Similar Documents

Publication Publication Date Title
JP2014516536A5 (OSRAM)
RU2013152648A (ru) Аденовирус обезьян и гибридные аденовирусные векторы
CN1067722C (zh) 腺病毒载体
JP6970647B2 (ja) シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法
JP6970059B2 (ja) アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
JP2015057052A5 (OSRAM)
JP2017514483A5 (OSRAM)
JP2020511940A5 (OSRAM)
CN102586327B (zh) 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN104212802B (zh) 一种肿瘤细胞广谱高活性启动子及其用途
CA2779632A1 (en) Simian adenovirus and methods of use
CN104846013A (zh) 一种复制缺陷型人55型腺病毒载体及其制备方法和应用
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
JP2005536231A (ja) アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用
JP2020537526A (ja) Rsv抗原性タンパク質又はその断片をコードする2つの発現カセットを有するアデノウイルスベクター
JP2021500880A (ja) 2つの発現カセットを有するサルアデノウイルスベクター
JP2000157289A5 (OSRAM)
Wen et al. Construction and immune evaluation of the recombinant duck adenovirus type 3 delivering capsid protein VP1 of the type 1 duck hepatitis virus
CN103555765A (zh) 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
JP2024501841A (ja) アデノウイルス血清型35ヘルパーベクター
JP2022552870A (ja) 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス
CN117417962B (zh) 一种多靶点溶瘤腺病毒的构建方法及应用
JP6153205B2 (ja) Va遺伝子破壊アデノウイルスベクターおよびそれを調製するための前駆体ベクター
JP7711050B2 (ja) アデノウイルスベクターおよびその使用
CN1231598C (zh) 一种重组禽腺病毒的制备方法